287 filings
Page 4 of 15
8-K
z15ictqlxnscae00bqyx
11 Aug 21
FibroGen Receives Complete Response Letter from the FDA for Roxadustat for Anemia of Chronic Kidney Disease
8:30am
S-8
2le3z kq1p9zjmlyx
9 Aug 21
Registration of securities for employees
5:28pm
8-K
ihbw4pk2vj1ddd
9 Aug 21
FibroGen Reports Second Quarter 2021 Financial Results
4:05pm
8-K
aq9nbawpp7g6xp
20 Jul 21
Entry into a Material Definitive Agreement
4:05pm
8-K
u2uzliamdig09 zd3
25 Jun 21
Astellas Receives Positive CHMP Opinion for EVRENZOTM (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease
5:26pm
8-K
94hli hf4
17 Jun 21
FibroGen and HiFiBiO Announce Transformative Partnership to
4:16pm
8-K
rsevqw8evuaiu0lada
7 Jun 21
Entry into a Material Definitive Agreement
4:32pm
8-K
djrev9 swgazwyg0sv
27 May 21
Submission of Matters to a Vote of Security Holders
4:09pm
8-K
iyk4mig
14 May 21
Regulation FD Disclosure
5:22pm
8-K
iee z37ptlx
10 May 21
FibroGen Reports First Quarter 2021 Financial Results
4:07pm
8-K
17hjut eocp9duli
13 Apr 21
Departure of Directors or Certain Officers
4:22pm
DEFA14A
jfa23lo70yj
13 Apr 21
Additional proxy soliciting materials
4:15pm
8-K
cpo5v3ezv044
7 Apr 21
Regulation FD Disclosure
8:30am
8-K
voco5u8p2i jdx
6 Apr 21
Company Continues to be Confident in the Benefit / Risk Profile of Roxadustat
4:59pm
SEC STAFF
f0n3b
29 Mar 21
SEC staff action: Order
12:00am
8-K
h14 fk9lsjumb
1 Mar 21
FibroGen Reports Fourth Quarter and Full Year 2020 Financial Results
4:06pm
SEC STAFF
if0bx
1 Mar 21
SEC staff action: Order
12:00am